drugset / Trial / NCT05863104

Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

NCT05863104

Phase 2 Completed 44 enrolled Dr. August Wolff GmbH & Co. KG Arzneimittel
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.

Timeline

Start
2023-03-07
Primary completion
2024-03-06
Completion
2024-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrronium Unknown 1 % Topical